Cargando…
Yttrium-90-Labeled Anti-Glypican 3 Radioimmunotherapy Halts Tumor Growth in an Orthotopic Xenograft Model of Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the second most lethal malignancy globally and is increasing in incidence in the United States. Unfortunately, there are few effective systemic treatment options, particularly for disseminated disease. Glypican-3 (GPC3) is a proteoglycan cell surface receptor overex...
Autores principales: | Ludwig, Andrew D., Labadie, Kevin P., Seo, Y. David, Hamlin, Donald K., Nguyen, Holly M., Mahadev, Vimukta M., Yeung, Raymond S., Wilbur, D. S., Park, James O. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6766125/ https://www.ncbi.nlm.nih.gov/pubmed/31636665 http://dx.doi.org/10.1155/2019/4564707 |
Ejemplares similares
-
Radioimmunotherapy of colorectal carcinoma xenografts in nude mice with yttrium-90 A33 IgG and Tri-Fab (TFM).
por: Antoniw, P., et al.
Publicado: (1996) -
Radioimmunotherapy for solid tumors: spotlight on Glypican-1 as a radioimmunotherapy target
por: Sabanathan, Dhanusha, et al.
Publicado: (2021) -
Glypican-3 targeted delivery of (89)Zr and (90)Y as a theranostic radionuclide platform for hepatocellular carcinoma
por: Labadie, Kevin P., et al.
Publicado: (2021) -
Orthotopic xenografts of human melanoma and colonic and ovarian carcinoma in sheep to evaluate radioimmunotherapy.
por: Turner, J. H., et al.
Publicado: (1998) -
Glypican-3 targeted positron emission tomography detects sub-centimeter tumors in a xenograft model of hepatocellular carcinoma
por: Labadie, Kevin P., et al.
Publicado: (2023)